Bavarian Nordic has appointed new Chief Financial Officer, coming from a Nasdaq Stockholm exchange listed pharmaceutical company, Orexo AB, it said Thursday.
Henrik Juuel, who will also be an Executive Vice President of Bavarian Nordic is currently the CFO of Orexo AB, a role he has held since 2013. His arrival to Bavarian Nordic is expected in the fourth quarter of 2018.
As noted by the company welcoming the new Vice President, Juuel comes to Bavarian Nordic with extensive experience in life sciences and international business. Prior to joining Orexo, Juuel held senior positions at several large and diverse organizations including Group CFO of Virgin Mobile (Central and Eastern Europe), CFO of GN ReSound, and CFO of NNE Pharmaplan. He began his career at Novo Nordisk in 1992, and during his 15-year tenure with the company held several senior finance positions in Denmark and abroad.
“We are thrilled to welcome Henrik to Bavarian Nordic who brings a keen sense of strategy and portfolio management. His proven track record in life sciences and international business will be invaluable to us as we continue to grow and expand our infectious disease and oncology businesses,” said Paul Chaplin, President and CEO of Bavarian Nordic.
“I am honored and excited to join Bavarian Nordic. This is an exciting time for the Company with several ongoing studies and partnerships across infectious disease and oncology, and I look forward to working with the team to continue advancing the Company’s growing and diverse pipeline,” said Henrik Juuel.